185 related articles for article (PubMed ID: 33571827)
21. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.
He LJ; Zhu YB; Fan QZ; Miao DD; Zhang SP; Liu XP; Zhang C
Bioorg Med Chem Lett; 2019 Feb; 29(4):549-555. PubMed ID: 30630717
[TBL] [Abstract][Full Text] [Related]
22. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
Dale T; Clarke PA; Esdar C; Waalboer D; Adeniji-Popoola O; Ortiz-Ruiz MJ; Mallinger A; Samant RS; Czodrowski P; Musil D; Schwarz D; Schneider K; Stubbs M; Ewan K; Fraser E; TePoele R; Court W; Box G; Valenti M; de Haven Brandon A; Gowan S; Rohdich F; Raynaud F; Schneider R; Poeschke O; Blaukat A; Workman P; Schiemann K; Eccles SA; Wienke D; Blagg J
Nat Chem Biol; 2015 Dec; 11(12):973-980. PubMed ID: 26502155
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma.
Yuan K; Kuang W; Chen W; Ji M; Min W; Zhu Y; Hou Y; Wang X; Li J; Wang L; Yang P
Eur J Med Chem; 2022 Jan; 228():114024. PubMed ID: 34875521
[TBL] [Abstract][Full Text] [Related]
24. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
Jin Q; Zhang D; Gao M; Jiang C; Zhang J
Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
[TBL] [Abstract][Full Text] [Related]
25. Discovery of potent and selective CDK8 inhibitors through FBDD approach.
Han X; Jiang M; Zhou C; Zhou Z; Xu Z; Wang L; Mayweg AV; Niu R; Jin TG; Yang S
Bioorg Med Chem Lett; 2017 Sep; 27(18):4488-4492. PubMed ID: 28802632
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
Mallinger A; Schiemann K; Rink C; Stieber F; Calderini M; Crumpler S; Stubbs M; Adeniji-Popoola O; Poeschke O; Busch M; Czodrowski P; Musil D; Schwarz D; Ortiz-Ruiz MJ; Schneider R; Thai C; Valenti M; de Haven Brandon A; Burke R; Workman P; Dale T; Wienke D; Clarke PA; Esdar C; Raynaud FI; Eccles SA; Rohdich F; Blagg J
J Med Chem; 2016 Feb; 59(3):1078-101. PubMed ID: 26796641
[TBL] [Abstract][Full Text] [Related]
27. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
[TBL] [Abstract][Full Text] [Related]
28. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
29. In Search of Novel CDK8 Inhibitors by Virtual Screening.
Kumarasiri M; Teo T; Yu M; Philip S; Basnet SK; Albrecht H; Sykes MJ; Wang P; Wang S
J Chem Inf Model; 2017 Mar; 57(3):413-416. PubMed ID: 28191946
[TBL] [Abstract][Full Text] [Related]
30. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
31. Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.
Huang Z; Zhao B; Qin Z; Li Y; Wang T; Zhou W; Zheng J; Yang S; Shi Y; Fan Y; Xiang R
Eur J Med Chem; 2019 Nov; 181():111541. PubMed ID: 31382120
[TBL] [Abstract][Full Text] [Related]
32. A novel CDK8 inhibitor with poly-substituted pyridine core: Discovery and anti-inflammatory activity evaluation in vivo.
Chen X; Yan Y; Cheng X; Zhang Z; He C; Wu D; Zhao D; Liu X
Bioorg Chem; 2023 Apr; 133():106402. PubMed ID: 36791618
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.
Myers SM; Miller DC; Molyneux L; Arasta M; Bawn RH; Blackburn TJ; Cook SJ; Edwards N; Endicott JA; Golding BT; Griffin RJ; Hammonds T; Hardcastle IR; Harnor SJ; Heptinstall AB; Lochhead PA; Martin MP; Martin NC; Newell DR; Owen PJ; Pang LC; Reuillon T; Rigoreau LJM; Thomas HD; Tucker JA; Wang LZ; Wong AC; Noble MEM; Wedge SR; Cano C
Eur J Med Chem; 2019 Sep; 178():530-543. PubMed ID: 31212132
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety.
Abdel-Maksoud MS; El-Gamal MI; Gamal El-Din MM; Oh CH
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):97-109. PubMed ID: 30362383
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a novel oral type Ⅰ CDK8 inhibitor against acute myeloid leukemia.
Zhang XX; Yan YY; Ma X; Xiao Y; Lei CC; Wang YM; Liu C; Wang Q; Zhang XT; Cheng WD; Liu XH
Eur J Med Chem; 2023 May; 251():115214. PubMed ID: 36889252
[TBL] [Abstract][Full Text] [Related]
36. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
[TBL] [Abstract][Full Text] [Related]
37. Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer.
Kuramoto K; Yamada H; Shin T; Sawada Y; Azami H; Yamada T; Nagashima T; Ohnuki K
Bioorg Med Chem; 2020 Mar; 28(5):115307. PubMed ID: 32007387
[TBL] [Abstract][Full Text] [Related]
38. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
39. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.
Rzymski T; Mikula M; Żyłkiewicz E; Dreas A; Wiklik K; Gołas A; Wójcik K; Masiejczyk M; Wróbel A; Dolata I; Kitlińska A; Statkiewicz M; Kuklinska U; Goryca K; Sapała Ł; Grochowska A; Cabaj A; Szajewska-Skuta M; Gabor-Worwa E; Kucwaj K; Białas A; Radzimierski A; Combik M; Woyciechowski J; Mikulski M; Windak R; Ostrowski J; Brzózka K
Oncotarget; 2017 May; 8(20):33779-33795. PubMed ID: 28422713
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
